论文部分内容阅读
目的探讨替加环素对泛耐药鲍氏不动杆菌(XDRAB)或多耐药鲍氏不动杆菌(MDRAB)肺炎治疗的临床效果,为XDRAB或MDRAB肺炎治疗提供理论依据。方法分析2013年5月-2015年2月医院重症医学科(ICU)接受治疗的48例XDRAB或MDRAB感染患者的临床资料,对患者的病死率、细菌清除率以及临床有效率进行观察和比较,数据采用SPSS 19.0软件进行统计分析。结果 48株鲍氏不动杆菌对碳青霉烯类药物有极高的耐药性,耐药率均为100.00%;治疗后,鲍氏不动杆菌清除24株,清除率为50.00%,治疗有效24株,有效率为50.00%。结论常规抗耐药ABA感染的治疗失败后,可以尝试将替加环素作为一种抢救性的治疗选择,然而临床上还需更多更可靠的证据。
Objective To investigate the clinical efficacy of tigecycline in the treatment of Pancreatic AciBion-resistant Acinetobacter (XDRAB) or Multi-drug resistant Acinetobacter baumannii (MDRAB) pneumonia and to provide a theoretical basis for the treatment of XDRAB or MDRAB pneumonia. Methods The clinical data of 48 patients with XDRAB or MDRAB infection admitted to the Hospital Intensive Care Unit (ICU) from May 2013 to February 2015 were analyzed. The mortality, bacterial clearance rate and clinical efficiency of the patients were observed and compared. Data using SPSS 19.0 software for statistical analysis. Results 48 strains of Acinetobacter baumannii were highly resistant to carbapenems, and the drug resistance rate was 100.00%. After treatment, 24 strains of Acinetobacter baumannii were cleared with a clearance rate of 50.00% Effective 24 strains, the effective rate of 50.00%. Conclusion After the treatment of conventional anti-resistant ABA infection fails, try tigecycline as a salvage treatment option, however, more and more clinical evidence is needed.